Clinical Trial Update: Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 randomized study evaluating silibinin (Legalon SIL) in treatment-naive genotype 4 chronic hepatitis C patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Legalon SIL (silibinin)

Snippet

Sponsor: Rottapharm | Conditions: Hepatitis C, Chronic | Phase 2, Phase 3 | Status: WITHDRAWN